Skip to main content

Security report for ucbpharma.co.uk

UCB Pharma Ltd. · Healthcare · United Kingdom

Low risk. 2 critical or high findings in Security headers and SSL/TLS.

Security score

76/100

Risk levelLow

0–100, higher is better. How it is calculated

UCB Pharma Ltd. is a global biopharmaceutical company with a strong presence in the UK, focusing on neurological, immunological, and rare disease treatments. The website reflects a professional and patient-centric approach, highlighting research centers, clinical trials, and corporate information. The digital infrastructure is built on Drupal CMS with modern analytics and cookie consent tools, ensuring compliance with privacy regulations. Security posture is robust with HTTPS and security headers in place, though explicit security policies and incident response contacts are not published. Overall, the site is trustworthy and well-maintained, supporting UCB's market position as a leading healthcare provider.

Scanned

NIS2 and GDPR posture

GDPR outside view
83/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…
  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching ucbpharma.co.uk

This scan found 20 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. See sample alerts.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
67
Security headers
65
Email security
60
DNS health
80
Network security
100
GDPR outside view
83
Average
76

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Breach exposure

Leaked credentials and lookalike domains from OffSeq Breach. The counts are free; the detailed lists are paid add-ons.

Dark web exposure

Add-on

Leaked records that mention ucbpharma.co.uk, from OffSeq Breach.

No leaked records found

Breach holds no records for ucbpharma.co.uk right now. New leaks arrive continuously, so monitoring on Breach alerts you if that changes.

Monitor on Breach (opens in a new tab)

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

UCB operates in the healthcare sector with a focus on innovative pharmaceutical research and development. The UK site serves as a regional hub with significant R&D and commercial activities. The company targets patients, healthcare professionals, and researchers, leveraging clinical trials and partnerships to maintain competitive advantage. The website's linkage to global domains and patient support sites indicates a broad partnership ecosystem. The business model is research-driven with commercial product offerings and a strong emphasis on compliance and transparency.

Security posture

The website demonstrates a mature security posture with enforced HTTPS, comprehensive security headers, and a cookie consent mechanism aligned with GDPR. No exposed sensitive data or vulnerable libraries were detected. However, the absence of a public security policy, incident response contacts, and vulnerability disclosure reduces transparency. The WHOIS data is unavailable due to querying the 'www' subdomain, which is a minor inconsistency but does not indicate malicious intent. Overall, the security maturity is good but could be enhanced by publishing additional security governance information.

Recommendations

  1. Publish a dedicated security policy page outlining security practices and commitments.
  2. Provide clear incident response contact information to improve transparency and trust.
  3. Implement and publicize a vulnerability disclosure program or security.txt file.
  4. Add data protection officer contact details to comply fully with GDPR transparency requirements.
  5. Regularly audit third-party scripts and analytics tools to mitigate supply chain risks.

Contact details published on the site

Addresses
Legal name
UCB Pharma Ltd.
Registration number
No. 1472269
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
UCB Pharma Ltd.
Description
UCB is a global biopharmaceutical company dedicated to discovering and developing treatments that aim to transform the lives of people living with neurological and immunological conditions, as well as rare diseases. The UK hosts one of UCB's global discovery research centres and commercial affiliate.
Key services
Neurology treatments, Immunology treatments, Rare diseases treatments, Clinical trials
Content quality
good
Branding
consistent

Technology

Stack
Drupal CMS, JavaScript, Google Tag Manager, OneTrust Cookie Consent
Frameworks
Drupal
Performance
moderate
Mobile
good
Accessibility
good
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent mechanism
  • No exposed sensitive data in HTML
  • No visible vulnerable libraries

Analytics and tracking

Services
Siteimprove Analytics, Google Tag Manager
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Siteimprove Analytics
Marketing tools
OneTrust Cookie Consent
Transparency
good

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is fully accessible with rich content.
  2. Professional healthcare biopharma company site.
  3. Strong privacy and cookie compliance with OneTrust.
  4. No visible security or content blocking issues.
  5. WHOIS data unavailable due to query on subdomain 'www'.
  6. Multiple external trusted domains linked.
  7. No suspicious or malicious content detected.
Technical notes

Notes

The website uses Drupal CMS with a modern front-end including JavaScript libraries and Google Tag Manager for analytics. The site is mobile-optimized and accessible, with good SEO practices including meta tags and structured navigation. Performance is moderate, with asynchronous loading of scripts and cookie consent managed by OneTrust. Hosting provider details are not explicitly identified. The technical stack is stable and supports the business needs effectively, though continuous monitoring and updates are recommended to maintain security and performance.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with ucbpharma.co.uk. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review ucbpharma.co.uk.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.